Cerenis Therapeutics

Contact
cerenis.com
+33562249706

Cerenis Therapeutics SA

Rue de la Découverte
31675 Labège
France
+33562249706
cerenis.com
Contact
Profile Products News
Contact

About Cerenis Therapeutics

Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on pioneering research conducted by the Cerenis team of world leaders in HDL therapy, the company is pursuing a range of HDL product candidates that are positioned to represent major advances in patient care and significant commercial opportunities in the treatment of cardiovascular and metabolic diseases. Cerenis has operations in Toulouse, France and Ann Arbor, Michigan.

Read more about Cerenis Therapeutics
Facts about Cerenis Therapeutics
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Cerenis Therapeutics

Product portfolio

Show all

News about Cerenis Therapeutics

Cerenis Therapeutics

24-Nov-2011 | people

Cerenis Appoints John F. Paolini as Chief Medical Officer

Cerenis Therapeutics announced the appointment of John F. Paolini, MD, PhD, FACC as Chief Medical Officer.Dr Paolini will be responsible for the strategic ...

Read news
Cerenis Therapeutics

17-Mar-2011 | research and development

Cerenis Initiates Phase 2 Study of Lead Product Candidate, CER-001, in Patients with Acute Coronary Syndrome

Cerenis Therapeutics announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis Regression?) study of CER-001 ...

Read news
Cerenis Therapeutics

22-Oct-2010 | business & finance

Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing

Cerenis Therapeutics announced it has raised a further €10 million in a second close of its Series C financing. This takes the total funds raised in the ...

Read news
Cerenis Therapeutics

28-Jul-2010 | business & finance

Cerenis Therapeutics raises €40 million in series C financing

Jean-Pierre Garnier appointed as non-executive director to the board

Read news
Cerenis Therapeutics

27-Jul-2010 | research and development

Cerenis and Novasep awarded €10.7 million funding from the French Government for the development CER-001, an HDL mimetic

Cerenis Therapeutics SA and Groupe Novasep announced that they have received French Government funding through OSEO to finance the development of CER-001, ...

Read news
Cerenis Therapeutics

23-Jun-2010 | research and development

Cerenis to Present Clinical Proof-of-Concept Results for CER-627 program (niacin/aspirin combinations)

Cerenis Therapeutics SA announced it will present the results of two clinical proof-of-concept studies for its CER-627 program (niacin/aspirin combinations ...

Read news
Cerenis Therapeutics

19-May-2010 | research and development

Cerenis Reports Positive Results for Phase 1 Study of CER-001, an HDL mimetic, for the Treatment of Cardiovascular Disease

Cerenis Therapeutics announced the completion of a Phase 1 study of the Company's CER-001 investigational product candidate to treat patients with acute ...

Read news
Cerenis Therapeutics

12-Feb-2009 | business & finance

Cerenis Therapeutics receives €2.5 million investment from French government through OSEO

Cerenis Therapeutics SA, a privately held pharmaceutical company, announced that it has received a €2.5 million investment to finance ongoing clinical ...

Read news
Show more news about Cerenis Therapeutics

Here you will find Cerenis Therapeutics SA